Intrapelvic low grade leiomyosarcoma with good prognosis


Creative Commons License

Serdar B., Meral K., Ugur S., Binnaz D., Namik D.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.41, no.3, pp.468-470, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.31083/j.ejgo.2020.03.4672
  • Journal Name: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE
  • Page Numbers: pp.468-470
  • Keywords: Intrapelvic leiomyosarcoma, Tumour receptors, Hormonotherapy, SURVIVAL, SARCOMA
  • Dokuz Eylül University Affiliated: Yes

Abstract

Soft tissue sarcomas (STS) are rare mesenchymal neoplasms arising from nonepithelial connective tissue origins. Retroperitoneal Soft tissue sarcomas may be primary tumours or metastases especially from the uterus. Here, the authors present a case of intrapelvic leiomyosarcoma treated with hormonotherapy after surgery. A 40-year-old multiparous woman was admitted to the hospital with abdominal pain. Abdominopelvic ultrasound was performed, and an uncircmuscribed mass was seen in the Douglas pouch. At laparotomy, a tumour measuring 7 cm in size, appearing as a sarcoma attached to the sigmoid colon serosa was found. The tumour was positive with H-caldesmon, actin, desmin, oestrogen and progesterone receptors (ER/PR). The patient with a diagnosis of low-grade intrapelvic leiomyosarcoma received adjuvant hormonotherapy after adjuvant radiotherapy. She is doing well without disease recurrence during a two-year follow-up period. Despite contradictory data according to recent limited investigations, the present authors suggest that ER and PR should be routinely quantified in STS by immunohistochemical methods, and it should be kept in mind that hormonotherapy may be a beneficial option.